101 related articles for article (PubMed ID: 34219681)
81. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial.
Peyrade F; Jardin F; Thieblemont C; Thyss A; Emile JF; Castaigne S; Coiffier B; Haioun C; Bologna S; Fitoussi O; Lepeu G; Fruchart C; Bordessoule D; Blanc M; Delarue R; Janvier M; Salles B; André M; Fournier M; Gaulard P; Tilly H;
Lancet Oncol; 2011 May; 12(5):460-8. PubMed ID: 21482186
[TBL] [Abstract][Full Text] [Related]
82. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.
Sehn LH; Donaldson J; Chhanabhai M; Fitzgerald C; Gill K; Klasa R; MacPherson N; O'Reilly S; Spinelli JJ; Sutherland J; Wilson KS; Gascoyne RD; Connors JM
J Clin Oncol; 2005 Aug; 23(22):5027-33. PubMed ID: 15955905
[TBL] [Abstract][Full Text] [Related]
83. Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL.
Hartert KT; Wenzl K; Krull JE; Manske M; Sarangi V; Asmann Y; Larson MC; Maurer MJ; Slager S; Macon WR; King RL; Feldman AL; Gandhi AK; Link BK; Habermann TM; Yang ZZ; Ansell SM; Cerhan JR; Witzig TE; Nowakowski GS; Novak AJ
Leukemia; 2021 Feb; 35(2):522-533. PubMed ID: 32139889
[TBL] [Abstract][Full Text] [Related]
84. VEGFA and VEGFR2 genetic polymorphisms and survival in patients with diffuse large B cell lymphoma.
Kim MK; Suh C; Chi HS; Cho HS; Bae YK; Lee KH; Lee GW; Kim IS; Eom HS; Kong SY; Bae SH; Ryoo HM; Shin IH; Mun YC; Chung H; Hyun MS
Cancer Sci; 2012 Mar; 103(3):497-503. PubMed ID: 22129133
[TBL] [Abstract][Full Text] [Related]
85. Primary myelofibrosis: rs2010963 VEGFA polymorphism favors a prefibrotic phenotype and is associated with higher risk of thrombosis.
Villani L; Rosti V; Massa M; Campanelli R; Catarsi P; Carolei A; Abbà C; De Silvestri A; Gale RP; Barosi G
Leuk Res; 2021 Dec; 111():106730. PubMed ID: 34700050
[No Abstract] [Full Text] [Related]
86. Nucleotide excision DNA repair pathway as a therapeutic target in patients with high-risk diffuse large B cell lymphoma.
Bret C; Klein B; Moreaux J
Cell Cycle; 2013 Jun; 12(12):1811-2. PubMed ID: 23708513
[No Abstract] [Full Text] [Related]
87. A novel angiogenesis-related scoring model predicts prognosis risk and treatment responsiveness in diffuse large B-cell lymphoma.
Liu Y; Wang J; Shen X; Li L; Zhang N; Wang X; Tang B
Clin Exp Med; 2023 Nov; 23(7):3781-3797. PubMed ID: 37402040
[TBL] [Abstract][Full Text] [Related]
88. Drug-Resistance Mechanism and New Targeted Drugs and Treatments of Relapse and Refractory DLBCL.
Zhang J; Gu Y; Chen B
Cancer Manag Res; 2023; 15():245-255. PubMed ID: 36873252
[TBL] [Abstract][Full Text] [Related]
89. Angiogenesis' related genetic variants alter clinical features and prognosis of diffuse large B-cell lymphoma patients.
Brito ABC; Delamain MT; Fanelli MF; Soares FA; de Souza CA; Vassallo J; Lima CSP
Tumour Biol; 2021; 43(1):129-140. PubMed ID: 34219681
[TBL] [Abstract][Full Text] [Related]
90. Adverse prognostic impact of vascular endothelial growth factor gene polymorphisms in patients with diffuse large B-cell lymphoma.
Yoon KA; Kim MK; Eom HS; Lee H; Park WS; Sohn JY; Kim MJ; Kong SY
Leuk Lymphoma; 2017 Nov; 58(11):2677-2682. PubMed ID: 28326867
[TBL] [Abstract][Full Text] [Related]
91. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
92. Polymorphisms in cytokine genes as prognostic markers in diffuse large B cell lymphoma patients treated with (R)-CHOP.
Liu D; Wang Y; Dong M; Guan S; Wang Y; Sun H; Wu N; Li S; Bai J; Chen F; Sun D; Jin Y
Ann Hematol; 2017 Feb; 96(2):227-235. PubMed ID: 27822610
[TBL] [Abstract][Full Text] [Related]
93. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
Johnston PB; LaPlant B; McPhail E; Habermann TM; Inwards DJ; Micallef IN; Colgan JP; Nowakowski GS; Ansell SM; Witzig TE
Lancet Haematol; 2016 Jul; 3(7):e309-16. PubMed ID: 27374464
[TBL] [Abstract][Full Text] [Related]
94. Association of interleukin-10, tumor necrosis factor-α and transforming growth factor-β gene polymorphisms with the outcome of diffuse large B-cell lymphomas.
Tarabar O; Cikota-Aleksić B; Tukić L; Milanović N; Aleksić A; Magić Z
Int J Clin Oncol; 2014 Feb; 19(1):186-92. PubMed ID: 23532628
[TBL] [Abstract][Full Text] [Related]
95.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
96.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
97.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
98.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
99.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
100.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
